World's 2nd KRAS Inhibitor Approved For Non-Small Cell Lung Cancer With 80% Efficacy!
More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!
New Research Shows Promise For Bone Marrow Transplant Recipient Patients To Reduce Treatment Side Effects!
Over 30% Of Tumours In Advanced Lung Cancer Patients In Remission With Frontier Drug Teliso-V In Combination With Troche!
Specialising in RNA 3D structure prediction, Atomic AI wants to launch an RNA version of AlphaFold to accelerate drug discovery!
The Prerequisite For a Handsome Man: a Healthy Prostate
